INVO Fertility (IVF) Registration Filing summary

Company overview and business model

• Operates as a healthcare services and technology company focused on expanding access to assisted reproductive technology (ART) through fertility clinics and proprietary INVOcell® device for intravaginal culture (IVC) procedures.

• Strategy includes building, acquiring, and operating fertility clinics, with a shift from device sales to clinic-based services for higher revenue per cycle.

• Owns two INVO Centers and one IVF clinic in the U.S., with plans to open additional wholly owned centers in underserved markets.

• INVOcell device enables in vivo fertilization, offering a more affordable and intimate alternative to traditional IVF, with comparable success rates.

• Recent divestiture of NAYA Therapeutics refocused the business exclusively on fertility services.

Financial performance and metrics

• Acquisition of Wisconsin Fertility Institute in August 2023 more than tripled annual revenue and added significant positive cash flow.

• Gross proceeds from the exercise of existing warrants in January 2026 totaled approximately $7.5 million before expenses.

• May receive up to $15,053,255 in gross proceeds upon full exercise of the Inducement Warrant.

Use of proceeds and capital allocation

• Proceeds from warrant exercises intended for acquisitions of additional fertility clinics, capital expenditures, working capital, and general and administrative expenses.

• Management has broad discretion over use of proceeds, which may not necessarily improve operating results.